以利妥昔单抗为主和以硼替佐米为主的治疗方案在淋巴浆细胞淋巴瘤中的疗效对比  

Comparison of Rituximab Versus Bortezomib-Based Regimens in Patients with Lymphoplasmacytic Lymphoma

作　　者：王秀峰 李婷[2] 字友梅[1] 王莉华[1] 刘宪凯 杨满[1] 郭燕[1] 吴隼[1] 黄琰[1] WANG Xiufeng;LI Ting;ZI Youmei;WANG Lihua;LIU Xiankai;YANG Man;GUO Yan;WU Sun;HUANG Yan(Department of Hematology,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of lymphoma,Xinxiang 453100,China;Department of Blood purification,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)

机构地区：[1]新乡医学院第一附属医院血液科,新乡市淋巴瘤分子诊疗重点实验室,河南新乡453100 [2]新乡医学院第一附属医院血液净化室,河南新乡453100

出　　处：《河南医学研究》2024年第3期400-404,共5页Henan Medical Research

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20210533);新乡市科技攻关项目(GG2020029)。

摘　　要：目的 评价以利妥昔单抗为主和以硼替佐米为主的治疗方案在淋巴浆细胞淋巴瘤中的疗效对比。方法 回顾分析2018年10月至2022年12月新乡医学院第一附属医院诊治的48例淋巴浆细胞淋巴瘤患者,其中以利妥昔单抗为主组(23例)和以硼替佐米为主组(25例)。比较两组疾病有效率和无疾病进展时间(PFS),并观察两组患者治疗期间不良反应发生情况。结果 以利妥昔单抗为主和以硼替佐米为主的化疗方案有效率差异无统计学意义(P>0.05),但以利妥昔单抗为主较以硼替佐米为主的化疗方案PFS时间延长(P<0.05)。不良反应方面,以利妥昔单抗为主治疗方不良反应主要为血细胞减少和感染,以硼替佐米为主的化疗方案不良反应主要为周围神经损伤和消化道反应的便秘和腹泻。结论 利妥昔单抗和硼替佐米均可应用于淋巴浆细胞淋巴瘤的治疗,但两组优劣性各有不同。Objective To evaluate the efficacy of rituximab based regimen and bortezomib based regimen in lymphoplasmacytic lymphoma.Methods A retrospective analysis was performed on 48 patients with lymphoplasmacytic lymphoma treated in the First Affiliated Hospital of Xinxiang Medical College from October 2018 to December 2022.Among them,rituximab was the main treatment group(23 cases)and bortezomib was the main chemotherapy group(25 cases).Objective response rate and progression free survival(PFS)were compared between the two groups,and the occurrence of adverse reactions during treatment was observed between the two groups.Results There was no significant difference in remission rate between rituximab chemotherapy regimen and bortezomib chemotherapy regimen(P>0.05),but the duration of PFS in rituximab chemotherapy regimen was longer than that in bortezomib chemotherapy regimen(P<0.05).The side effects of rituximab were mainly hemocytopenia and infection.The side effects of bortezomib-based chemotherapy were mainly peripheral nerve injury and digestive tract reaction constipation and diarrhea.Conclusion Rituximab and bortezomib can be used in the treatment of lymphoplasmacytic lymphoma,but the advantages and disadvantages of the two groups are different.

关 键 词：利妥昔单抗 硼替佐米 淋巴浆细胞淋巴瘤 

分 类 号：R551.2[医药卫生—血液循环系统疾病]